Charles Theuer - Mar 12, 2024 Form 4 Insider Report for Tracon Pharmaceuticals, Inc. (TCON)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Scott B. Brown, Attorney-in-Fact
Stock symbol
TCON
Transactions as of
Mar 12, 2024
Transactions value $
$949
Form type
4
Date filed
3/13/2024, 05:56 PM
Previous filing
Jun 30, 2023
Next filing
May 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCON Common Stock Award $482 +3.5K +0.88% $0.14 403K Apr 20, 2023 Direct F1
transaction TCON Common Stock Award $467 +3.5K +0.87% $0.13 406K Oct 20, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCON Employee Stock Option (Right to Buy) Award $0 +518K $0.00 518K Mar 12, 2024 Common Stock 518K $0.39 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2023.
F2 Shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on October 20, 2023.
F3 1/4th of the shares subject to this option shall vest on the first anniversary of the Grant Date shown in column 3 above. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter, on the last day of each month.